Donate Now
Beginning in fall 2022, pediatric, adolescent and young adult patients with cancer and blood disorders in the greater Pacific Northwest will be cared for at a new state-of-the-art facility specifically designed for transformative, patient-centered care.
Starting today, Seattle Children’s is offering appointments to children between the ages of 6 months and 5 years (under 6 years old) to receive the Pfizer-BioNTech and Moderna COVID-19 vaccines, based on recent approvals from the CDC, Washington State Department of Health and the Western States Scientific Safety Review Workgroup. We are grateful to be able to offer COVID-19 vaccines to young patients.
We are pleased to announce the launch of a new intensive outpatient program (IOP) at Seattle Children’s for patients with eating disorders. The Eating Disorders IOP is designed for children and youth with high-acuity eating disorders who don’t require inpatient care but need more than typical outpatient care can provide.
Seattle Children’s Therapeutics has opened a new study that will evaluate the safety and feasibility of CAR T-cell immunotherapy in patients with bone cancer. The ENLIGHTen-01 study is approved for patients ages 15 to 30 years old who have refractory or progressive osteosarcoma. It is Seattle Children’s first study of CAR T-cell therapy for this patient population.
From: Dr. Jay Santos, Urgent Care Medical Director and Dr. Tony Woodward, ED Medical Director
We’re excited to announce a June 1, 2022 opening for the first finished spaces of Seattle Children’s much-anticipated new addition — formerly called Building Care during construction and now referred to as Forest B (our buildings’ zones are Forest, Mountain, River and Ocean). The finished spaces include a parking garage for patients and families and a new main lobby that will serve as our 24/7 main entrance. The current main entrance will still be open to patients and families daily until 10 p.m.
We are thrilled to share that the recently announced restructure of our region’s cancer partnership and the transfer of SCCA’s outpatient Pediatric Blood and Marrow Transplant Program to Seattle Children’s will bring all pediatric cancer and blood disorder programs under one roof at Seattle Children’s.
From: Dr. Elaine Albert, Medical Director, Inpatient Access and Dinarte Viveiros, Vice President of Patient Care Services and Associate Chief Nurse, Inpatient and Emergency Services
Measles Mimics
Seattle Children's complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.
© 1995—2022 Seattle Children's Hospital
